New Phase 3 data presented at ESMO show that the Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) combination extends overall survival in locally advanced or metastatic bladder cancer. The results build on prior confirmatory data and suggest the antibody‑drug conjugate–checkpoint inhibitor pairing may set a new standard for certain patient populations. Investigators reported survival and progression‑free survival improvements versus control arms, and discussed tolerability in the trial cohorts. The findings could influence label updates and reimbursement discussions for combinations of ADCs with immunotherapy in urothelial carcinoma.